Alaunos Therapeutics, Inc. stock is down -17% since 30 days ago. The next earnings date is Mar 5, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 36.84% of the previous 18 December’s closed higher than November. In the last 1 Unusual Options Trades, there were 1 PUT.
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR. The company was formerly known as ZIOPHARM Oncology, Inc.